A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Clinical trial NCT05520567 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05520567
Sponsor: Astellas Pharma Global Development, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia

Start date: 2023-01-31
Primary completion: 2028-07-31
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.